Since the awareness was brought up
earlier I thought I add the importance of it.
In order to find the patients both doctors and patients need to be educated about higher prevalence/progression
and co morbidities of the these conditions(HIV lipodystrophy/NAFLD and NASH...).
PLWH are at higher risk of suffering from lipodystrophy(acquired) which can cause other metabolic diseases including NASH.
Being undiagnosed for "14 years" is unacceptable and could lead to many undiagnosed serious health problems some irreversible(listed below). To put it in perspective in North America patients of certain age and family history with or without colon cancer are recommended to perform colonoscopy with various intervals depending on their risk factors same methodology(regular testing)should apply to PLWH with or without history of metabolic disorders for typical common diseases including lipodystrophy and NASH among others.
"In general, for this condition, it can take an average of more than 14 years before a diagnosis is found, he points out.
Because lipodystrophy is a metabolic disease, it is urgent to work on reducing diagnostic times, so as to facilitate a comprehensive approach to the multiple manifestations and clinical complications, such as: diabetes mellitus, coronary and cardiovascular disease, liver compromise leading to severe degeneration of the liver, fatty liver, pancreatitis, enlargement of the hands, feet, and jaw, dark velvety-looking patches on the skin, and bone age beyond the age of the patient."
Lipodystrophy, a disease that prevents you from stopping eating-breakinglatest.news-Breaking Latest News
" What You Need to Know
Background Aging human immunodeficiency virus (HIV)-monoinfected patients with metabolic syndrome, abnormal liver enzymes, or lipodystrophy are considered at risk of nonalcoholic fatty liver disease, but the severity and risk factors of liver steatosis and fibrosis remain debated in this population. Findings Moderate to severe steatosis (magnetic resonance imaging proton density fat fraction 10%) (36%) and advanced fibrosis (Fibroscan 9.6kPa) (11%) are frequent. High body mass index and aminotransferase are associated with advanced fibrosis. Implications for patient care Aging HIV-monoinfected patients with metabolic disorders or abnormal liver enzymes should be systematically screened for liver steatosis and fibrosis. The controlled attenuation parameter technique can be used to identify patients with moderate to severe steatosis."
https://www.binasss.sa.cr/mar23/20.pdf